100Plus

100Plus

Personalized health prediction company using data analytics and game mechanics for healthy living of individuals. Learn more

Launch date
Employees
Market cap
-
Enterprise valuation
AUD155—232m (Dealroom.co estimates Mar 2021.)
San Francisco California (HQ)
  • Edit
DateInvestorsAmountRound
-

N/A

-

$500k

Seed

$750k

Acquisition

N/A

Acquisition

$25.0m

Seed

N/A

Acquisition
Total FundingAUD39.4m

Recent News about 100Plus

Edit
More about 100Plusinfo icon
Edit

100Plus operates in the healthcare technology sector, specializing in remote patient monitoring (RPM) solutions. The company leverages artificial intelligence to enhance patient engagement and streamline healthcare workflows. Its core product is an AI-assisted RPM platform that includes features such as a new patient portal, SDOH (Social Determinants of Health) surveys, and innovative reporting capabilities. The platform is designed to improve patient outcomes by reducing hospitalizations and other high-acuity care incidents. The primary clients are healthcare providers, including clinics and hospitals, who benefit from improved patient monitoring and engagement. The business model is subscription-based, where healthcare providers pay for access to the RPM platform and its features. Revenue is generated through these subscriptions and potentially through additional services such as training and support. The market for 100Plus includes healthcare providers in the United States, particularly those looking to adopt advanced RPM technologies to improve patient care and reduce costs. The company also provides educational resources on RPM reimbursement, helping providers understand billing codes and reimbursement rates from Medicare.

Keywords: AI-assisted, remote patient monitoring, healthcare technology, patient engagement, SDOH surveys, reporting capabilities, subscription model, Medicare reimbursement, healthcare providers, patient outcomes.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.